EA029539B8 - Фармацевтическая композиция ситаглиптина - Google Patents

Фармацевтическая композиция ситаглиптина

Info

Publication number
EA029539B8
EA029539B8 EA201391371A EA201391371A EA029539B8 EA 029539 B8 EA029539 B8 EA 029539B8 EA 201391371 A EA201391371 A EA 201391371A EA 201391371 A EA201391371 A EA 201391371A EA 029539 B8 EA029539 B8 EA 029539B8
Authority
EA
Eurasian Patent Office
Prior art keywords
sitagliptin
pharmaceutical composition
pharmaceutical compositions
compositions
processes
Prior art date
Application number
EA201391371A
Other languages
English (en)
Other versions
EA029539B1 (ru
EA201391371A1 (ru
Inventor
Мая Прескар
Весна Крошель
Сабина Трошт
Луция Хвалец
Ален Кляйиц
Полона Буковец
Original Assignee
Крка, Товарна Здравил, Д.Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Товарна Здравил, Д.Д., Ново Место filed Critical Крка, Товарна Здравил, Д.Д., Ново Место
Publication of EA201391371A1 publication Critical patent/EA201391371A1/ru
Publication of EA029539B1 publication Critical patent/EA029539B1/ru
Publication of EA029539B8 publication Critical patent/EA029539B8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к стабильным фармацевтическим композициям, содержащим аморфный ситаглиптин, а также к способам получения этих композиций. Фармацевтические композиции получают из раствора, содержащего ситаглиптин и ингибитор кристаллизации.
EA201391371A 2011-03-29 2012-03-29 Фармацевтическая композиция ситаглиптина EA029539B8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI201100115 2011-03-29
PCT/EP2012/055736 WO2012131005A1 (en) 2011-03-29 2012-03-29 Pharmaceutical composition of sitagliptin

Publications (3)

Publication Number Publication Date
EA201391371A1 EA201391371A1 (ru) 2014-02-28
EA029539B1 EA029539B1 (ru) 2018-04-30
EA029539B8 true EA029539B8 (ru) 2018-06-29

Family

ID=45922684

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391371A EA029539B8 (ru) 2011-03-29 2012-03-29 Фармацевтическая композиция ситаглиптина

Country Status (4)

Country Link
EP (1) EP2691083B1 (ru)
EA (1) EA029539B8 (ru)
SI (1) SI2691083T1 (ru)
WO (1) WO2012131005A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013084210A1 (en) * 2011-12-08 2013-06-13 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
IN2014MU00212A (ru) * 2014-01-21 2015-08-28 Cadila Healthcare Ltd
WO2015114152A1 (en) * 2014-02-03 2015-08-06 Galenicum Health S.L. Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
IN2014MU00651A (ru) * 2014-02-25 2015-10-23 Cadila Healthcare Ltd
CN108144065B (zh) * 2016-12-06 2023-05-16 江苏恒瑞医药股份有限公司 一种dpp-4抑制剂的药物组合物
MX2016016260A (es) 2016-12-08 2018-06-07 Alparis Sa De Cv Nuevas formas solidas de sitagliptina.
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
WO2021076066A1 (en) 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
EP3811930A1 (en) * 2019-10-24 2021-04-28 Authenda Pharmaceuticals AG Oral gliptin compositions and method for preparation thereof
GR1010089B (el) 2020-09-15 2021-09-27 Φαρματεν Α.Β.Ε.Ε. Στερεη φαρμακοτεχνικη μορφη περιεχουσα σιταγλιπτινη και μεθοδος παρασκευης αυτης
CN116459227B (zh) * 2023-05-11 2024-07-26 宙晟智维生命科学(上海)有限公司 一种西格列汀片及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033848A1 (en) * 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
WO2008000418A2 (en) * 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
US20100249140A1 (en) * 2009-03-30 2010-09-30 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
WO2011127106A1 (en) * 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2012031124A2 (en) * 2010-09-03 2012-03-08 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2012076973A2 (en) * 2010-12-09 2012-06-14 Aurobindo Pharma Limited Novel salts of dipeptidyl peptidase iv inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2007504230A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
EP1667524A4 (en) 2003-09-23 2009-01-14 Merck & Co Inc NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTASE-IV INHIBITOR
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
EP1909776A2 (en) 2005-07-25 2008-04-16 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
KR20070111099A (ko) 2006-05-16 2007-11-21 영진약품공업주식회사 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
WO2009084024A2 (en) 2007-11-02 2009-07-09 Glenmark Generics Limited A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2009070314A2 (en) 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystalline form of sitagliptin
EP2599781A1 (en) 2007-12-20 2013-06-05 Dr. Reddy's Laboratories Ltd. Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
US20100041885A1 (en) 2008-03-25 2010-02-18 Nurit Perlman Crystalline forms of sitagliptin phosphate
US20090247532A1 (en) 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
KR20110038011A (ko) 2008-07-03 2011-04-13 라티오팜 게엠베하 시타글립틴의 결정질 염
EP2324027B1 (en) 2008-07-29 2016-02-24 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
EP2331545B1 (en) 2008-08-27 2013-10-02 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine&new impurities in preparation thereof
EP2218721A1 (en) 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
WO2010122578A2 (en) 2009-04-20 2010-10-28 Msn Laboratories Limited Process for the preparation of sitagliptin and its intermediates
CA2759196A1 (en) 2009-05-11 2010-11-18 Generics [Uk] Limited Novel crystalline polymorph of sitagliptin dihydrogen phosphate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033848A1 (en) * 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2008000418A2 (en) * 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
US20100249140A1 (en) * 2009-03-30 2010-09-30 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
WO2011127106A1 (en) * 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2012031124A2 (en) * 2010-09-03 2012-03-08 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2012076973A2 (en) * 2010-12-09 2012-06-14 Aurobindo Pharma Limited Novel salts of dipeptidyl peptidase iv inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROADHEAD J, EDMOND ROUAN S K, RHODES C T: "THE SPRAY DRYING OF PHARMACEUTICALS", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, vol. 18, no. 11/12, 1 January 1992 (1992-01-01), US, pages 1169 - 1206, XP009030193, ISSN: 0363-9045, DOI: 10.3109/03639049209046327 *
PATTERSON, J.E. JAMES, M.B. FORSTER, A.H. LANCASTER, R.W. BUTLER, J.M. RADES, T.: "Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 336, no. 1, 12 April 2007 (2007-04-12), NL, pages 22 - 34, XP022026284, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2006.11.030 *

Also Published As

Publication number Publication date
EP2691083B1 (en) 2017-08-02
WO2012131005A1 (en) 2012-10-04
SI2691083T1 (sl) 2017-12-29
EA029539B1 (ru) 2018-04-30
EA201391371A1 (ru) 2014-02-28
EP2691083A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
EA029539B8 (ru) Фармацевтическая композиция ситаглиптина
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
MD20150091A2 (ru) Противовирусные соединения
PH12014502733A1 (en) Neprilysin inhibitors
ZA201306221B (en) Compounds and compositions as trk inhibitors
IN2014CN04530A (ru)
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
MY165087A (en) Neprilysin inhibitors
IL222199A0 (en) Process for preparation of dopo-derived compounds and compositions thereof
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
EP2680848A4 (en) STABLE TETRAHYDROBIOPTERINE COMPOSITIONS
MX2011012232A (es) Formas de dosificacion liquidas de isotretinoina.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX362879B (es) Usos novedosos.
IN2015DN00833A (ru)
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
IN2014DN03245A (ru)
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
EP2575465A4 (en) Raltegravir SALTS
EP2611446A4 (en) CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR THE PREPARATION OF THE AMORPHOUS FORM OF MARAVIROC
MX2014012886A (es) Composiciones farmaceuticas de liberacion retardada de salsalato.
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir
EP2543373A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND
GB201100786D0 (en) Pharmaceutical compositions of immunosuppressants

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM